Impact of transitory hyperprolactinemia on clinical outcome of in vitro fertilization and embryo transfer

• Main Authors: Zhong Yi-Ping, Shen Xiao Ting, Ying Ying, Hai-Tao Wu, Jin Li, Quan Qi, Zhou Can-Quan, Zhuang Guang-Lun
• Format: Article
• Language: English
• Published: Society of Medical Biochemists of Serbia, Belgrade 2012-01-01
• Series: Journal of Medical Biochemistry
• Subjects: hyperprolactinemia; in vitro fertilization and embryo transfer; human chorionic gonadotropin; clinical pregnancy
• Online Access: https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2012/1452-82581201027Z.pdf
• ISSN: 1452-8258; 1452-8266

This study aimed to evaluate the impact of serum prolactin concentration at the day of human chorionic gonadotropin (HCG) administration on the clinical outcome of in vitro fertilization and embryo transfer (IVF-ET). A total of 184 patients receiving the IVF-ET/ICSI-ET from October 2005 to March 2008 were retrospectively analyzed. Subjects were divided into four groups according to the serum prolactin concentration [<30 ng/mL (A), 30-60 ng/mL (B), 60-90 ng/mL (C), ≥90 ng/mL (D)] on the day of HCG administration during controlled ovarian stimulation (COS). In the Groups A, B, C and D, the implantation rate was 11.76%, 19.71%, 12.72% and 2.22%, respectively, and the pregnancy rate (PR) was 25.00%, 42.70%, 27.30% and 5.88%, respectively. The implantation rate and PR in the Group D were markedly lower than those in the remaining groups (P=0.011 and 0.009). During the COS, the serum prolactin concentration was dramatically elevated when compared with the base line level leading to transient hyperprolactinemia. In addition, the implantation rate and pregnancy rate were significantly markedly decreased when the serum prolactin concentration was remarkably increased (≥90 ng/mL). To improve the clinical pregnancy rate of IVF-ET, close monitoring and appropriate intervention are needed for patients with an abnormal prolactin level during the COS.